NEJM Group Announces Jeffrey Drazen, M.D., to Retire

Dr. Drazen has led the New England Journal of Medicine since 2000

(Boston, Mass., September 27, 2018) — NEJM Group announced Thursday that Jeffrey M. Drazen, M.D., Editor-in-Chief of the New England Journal of Medicine, will retire within the next year. To ensure a smooth transition, Dr. Drazen will continue to lead the Journal and NEJM Group until a successor is named.

An international search committee has been identified and will begin work immediately on a worldwide search. Dr. Drazen will have an active part in the search process.

“This is the right time for a transition in leadership as the Journal looks toward the future,” said Dr. Drazen. “It has truly been an honor to serve as the Editor-in-Chief of the Journal and as the editorial head of NEJM Group. I am grateful for the opportunity to have played a part in continuing the Journal’s long tradition of excellence in medical publishing and in expanding the Journal’s reach worldwide. I have worked with a remarkable group of colleagues who share a deep commitment to medical knowledge and patient care.”

Dr. Drazen has led the Journal through the publication of many landmark studies, including articles on early peanut consumption in infants at risk for allergy, practice-changing research of trastuzumab for HER2-positive breast cancer, and the earliest research on Ebola virus disease in West Africa. He also initiated many digital innovations on NEJM.org, such as Interactive Medical Cases, Quick Take videos, and Clinical Decisions articles.

Dr. Drazen also helped develop policies that led to more transparency in scientific publishing, including mandating clinical trial registration, requiring financial disclosures for authors, and making trial protocols and statistical analysis plans available when research is published. In his role as Editor-in-Chief of NEJM Group, he has overseen the development of NEJM Knowledge+, NEJM Catalyst, NEJM Resident 360, and NEJM 医学前沿.

“Dr. Drazen’s tenure has been one of tremendous progress, noted accomplishments, and an unwavering sense of responsibility to patients,” said Alain A. Chaoui, M.D., President of the Massachusetts Medical Society, publisher of the New England Journal of Medicine. “We are indebted to Dr. Drazen for his visionary leadership, his unsurpassed scientific and clinical knowledge, and his deep commitment to this organization and its mission. We look forward to Dr. Drazen being part of the transition process.”
About the New England Journal of Medicine
The New England Journal of Medicine is the world’s leading medical journal and website. Continuously published for over 200 years, NEJM publishes peer-reviewed research and interactive clinical content for physicians, educators, and the global medical community. NEJM is a publication of NEJM Group, a division of the Massachusetts Medical Society. For more information, please visit http://www.nejm.org.

About the Massachusetts Medical Society
The Massachusetts Medical Society (MMS) is the statewide professional association for physicians and medical students, supporting 25,000 members. We are dedicated to educating and advocating for the physicians of Massachusetts and patients locally and nationally. A leadership voice in health care, the MMS contributes physician and patient perspectives to influence health-related legislation at the state and federal levels, works in support of public health, provides expert advice on physician practice management, and addresses issues of physician well-being. Under the auspices of NEJM Group, the MMS extends our mission globally by advancing medical knowledge from research to patient care through the New England Journal of Medicine, NEJM Catalyst, NEJM 医学前沿, and NEJM Journal Watch family of specialty publications, and through our education products for health care professionals: NEJM Knowledge+, NEJM Resident 360, and our accredited and comprehensive continuing medical education programs.